ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bicalutamide

Also written as “Bicalutamide”, “ICI176,334-1” and “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”.

Its studies are mostly in Prostatic Neoplasms · Lower Urinary Tract Symptoms · Puberty, Precocious · Gynecomastia, led by 5 companies.

Drug pageBicalutamide: every studyMany companies study it; this page follows only the 21 they lead. All 94 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 26, 200521 company-led studies, 1 open or runningNext primary completion: Apr 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only130 open or runningphase 4since Oct 26, 2005Oct 16, 2004none ahead
Alessa Therapeutics21 open or runningphase 1since Feb 12, 2020Feb 12, 2020Apr 24, 2027phase 1 · NCT04943536
Kremers Urban Developmentits history only20 open or runningphase 1since Dec 23, 2009Dec 23, 2009none ahead
Novartisits history only20 open or runningphase 1since Aug 13, 2009Aug 13, 2009none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Sep 8, 2009Sep 8, 2009none ahead

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alessa Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2020First study: phase 1 study in Lower Urinary Tract SymptomsFirst studyNCT04284761 · 17 enrolled · United States, Australia, New Zealand
  2. Jun 15, 2021Phase 1 study in Prostate AdenocarcinomaNCT04943536 · 20 enrolled · United States

Ahead

  1. Apr 24, 2027Primary completion: phase 1 study in Prostate AdenocarcinomaNCT04943536

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Alessa Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04943536Prostate Adenocarcinoma · United States1Active, not recruitingApr 24, 202720
NCT04284761Lower Urinary Tract Symptoms · United States, Australia, New Zealand1CompletedMay 3, 202317

How it is read

Names in the registry

  • “Bicalutamide”, 9 entries
  • “ICI176,334-1”, 4 entries
  • “bicalutamide”, 2 entries
  • “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”, 2 entries
  • “Casodex 80 mg tablet”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.